Loading
Life sciences · Journal article
Exploration of Asthma & Allergy · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The asthma-obstructive sleep apnea (OSA) overlap is a clinically important phenotype, especially in patients with severe or difficult-to-control asthma. Rather than a simple coexistence of independent conditions, this overlap represents a distinct clinical entity modulated by shared pathobiological pathways. This review integrates epidemiologic data, critically balancing association and causation across shared risk factors (obesity, GERD, upper airway disease). We construct an integrated mechanistic framework encompassing mechanical/neuroreflex interactions, intermittent hypoxia–driven inflammation/oxidative stress, and metabolic dysfunction. The overlap is associated with poorer asthma control, increased nocturnal symptoms, reduced quality of life, and higher healthcare utilization. Current evidence is largely observational; randomized controlled trials with respiratory endpoints and prospective cohorts with repeated polysomnography and biomarker panels are needed to establish strict bidirectional causality and identify responders to targeted therapies. A multidisciplinary, treatable-traits approach addressing OSA, obesity, rhinitis, GERD, and inhaler optimization is recommended while awaiting mechanistic and interventional data on CPAP, weight-loss therapies, and biologics.